Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm

University of Sao Paulo126 enrolled

Overview

The objective of this study is to evaluate predictors of response to antipsychotic medication in subjects with schizophrenia. The investigators will evaluate psychopathology,brain MRI, genetics and neuropsychological profile. Two groups of treatment will be compared: first generation antipsychotics vs. second generation antipsychotics. Participants will be randomized to one of the groups. Trial duration: 12 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

126

Conditions

Schizophrenia or Schizoaffective Disorder

Interventions

AntipsychoticsDRUG

Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg

AntipsychoticsDRUG

Haloperidol 2,5-10 mg; chlorpromazine 25-600 mg.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Schizophrenia or schizoaffective disorder * Age: 18-45 years olde * Less than 10 years of diagnosis * Acute exacerbation of psychotic symptoms Exclusion Criteria: * Use of clozapine * Clinical unstable disease * Delirium and cognitive disorders

Locations (1)

Instituto de Psiquiatria - Hospital das Clinicas FMUSP

São Paulo, São Paulo, Brazil

RECRUITING

Outcomes

Primary Outcomes

% responders to first generation antipsychotics vs. % responders to second generation antipsychotics

Time frame: 8-12 weeks

Secondary Outcomes

% of treatment abandon and respective causes

Time frame: 8-12 weeks

Central Contacts

Monica Kayo, MD

CONTACT

551130696971 monica.kayo@usp.br

Helio Elkis, PhD

CONTACT

551130696971 helkis@usp.br

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.